BM
BMXMF.US bioMérieux S.A
- Market cap
- USD 12.0B
- P/E
- 22.4x
- P/B
- 2.50x
- ROE
- 21.0%
- Dividend yield
- 1.11%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is BMXMF.US undervalued?
Graham numberBMXMF.US trades 58.1% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
bioMérieux S.A fundamental analysis
No fundamental analysis for bioMérieux S.A yet.
bioMérieux S.A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About bioMérieux S.A
bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments. The company offers CHROMID RANGE, a chromogen culture media; air, surface, and water monitoring systems; BACT/ALERT VIRTUO, a blood sample culture system; BIOFIRE, a multiplex polymeras…
Full company profilebioMérieux S.A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
bioMérieux S.A annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.10B | 2.29B | 2.42B | 2.67B | 3.12B | 3.38B | 3.59B | 3.67B | 3.98B | 4.07B | 7.85B |
| Gross Profit | 1.10B | 1.21B | 1.30B | 1.47B | 1.75B | 2.00B | 2.01B | 2.06B | 2.22B | 2.27B | 4.33B |
| Operating Income | 283M | 315M | 344M | 371M | 553M | 784M | 587M | 439M | 589M | 654M | 1.20B |
| EBITDA | 420M | 449M | 530M | 576M | 823M | 1.02B | 876M | 828M | 898M | 849M | 1.76B |
| Net Income | 179M | 238M | 257M | 273M | 404M | 601M | 452M | 358M | 432M | 397M | 903M |
| EPS | 1.52 | 2.01 | 2.17 | 2.30 | 3.41 | 5.06 | 3.82 | 3.01 | 3.64 | 3.34 | 7.63 |
| Balance Sheet | |||||||||||
| Total Assets | 3.03B | 2.99B | 3.39B | 3.78B | 3.93B | 4.62B | 5.19B | 5.26B | 5.77B | 5.57B | 5.69B |
| Total Liabilities | 1.41B | 1.25B | 1.39B | 1.53B | 1.45B | 1.44B | 1.54B | 1.51B | 1.56B | 1.47B | 1.39B |
| Shareholders' Equity | 1.62B | 1.74B | 1.93B | 2.20B | 2.43B | 3.12B | 3.60B | 3.75B | 4.20B | 4.10B | 4.29B |
| Cash & Short-term Investments | 179M | 312M | 280M | 275M | 389M | 804M | 553M | 352M | 450M | 570M | 657M |
| Total Debt | 453M | 468M | 547M | 592M | 481M | 463M | 505M | 519M | 491M | 461M | 421M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 336M | 358M | 387M | 408M | 583M | 811M | 475M | 445M | 667M | 788M | 1.74B |
| Capital Expenditure | 233M | 184M | 227M | 273M | 278M | 290M | 287M | 338M | 346M | 335M | 557M |
| Free Cash Flow | 103M | 174M | 160M | 135M | 305M | 521M | 188M | 107M | 322M | 453M | 1.19B |
| Ratios | |||||||||||
| ROE | 11.1% | 13.7% | 13.3% | 12.4% | 16.6% | 19.2% | 12.6% | 9.5% | 10.3% | 9.7% | 21.0% |
| ROA | 5.9% | 8.0% | 7.6% | 7.2% | 10.3% | 13.0% | 8.7% | 6.8% | 7.5% | 7.1% | 15.9% |
| Net Profit Margin | 8.5% | 10.4% | 10.6% | 10.2% | 13.0% | 17.8% | 12.6% | 9.7% | 10.9% | 9.8% | 11.5% |
| Debt to Equity | 0.28x | 0.27x | 0.28x | 0.27x | 0.20x | 0.15x | 0.14x | 0.14x | 0.12x | 0.11x | 0.10x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
bioMérieux S.A dividends
- Dividend yield
- 1.11%
- Forward dividend
- 1.13 USD
- Payout ratio
- 26.7%
- Ex-dividend date
- Jun 9, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | EUR 106M | 0.89 | 26.7% |
| 2024 | EUR 100M | 0.84 | 23.2% |
| 2023 | EUR 100M | 0.84 | 28.0% |
| 2022 | EUR 101M | 0.85 | 22.4% |
| 2021 | USD 73.1M | 0.61 | 12.2% |
| 2020 | USD 22.5M | 0.19 | 5.6% |
| 2019 | USD 41.3M | 0.35 | 15.1% |
| 2018 | USD 40.2M | 0.34 | 15.7% |
| 2017 | USD 39.4M | 0.33 | 16.5% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 3:1 on Sep 20, 2017.
Who owns bioMérieux S.A
- Insiders 66.46%
- Institutions 15.20%
- Public & others 18.34%
- Shares outstanding 118M
- Free float 40.0M
bioMérieux S.A company profile
- Company name
- bioMérieux S.A
- Ticker
- BMXMF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 14,562
- Fiscal year end
- December
- Address
- 376 Chemin De l?Orme, Marcy-l'Étoile, France, 69280
- Phone
- 33 4 78 87 20 00
- Website
- biomerieux.com
About bioMérieux S.A
bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments. The company offers CHROMID RANGE, a chromogen culture media; air, surface, and water monitoring systems; BACT/ALERT VIRTUO, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction system (PCR); BIOFIRE SPOTFIRE, a lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VITEK 2, an automated identification and antimicrobial susceptibility testing (AST) system; API RANGE standardized ID strips; VITEK REVEAL, a rapid AST system; ETEST, a gradient method on culture media; BIOMERIEUX EPISEQ CS, a whole genome sequencing solution for epidemiologic monitoring; VIDAS, a specific marker of severe bacterial infections/sepsis; and Biomérieux vision suite, a software that provides information to support diagnosis and clinical decision making. It also provides culture media and associated instruments; ARGENE that provides PCR tests for diagnosing viral respiratory diseases; EMAG system and NUCLISENS extraction reagents for DNA and RNA extraction; GENE-UP and VERIFLOW for detection of microorganisms for the food industry; ETEST for manual measurement of minimum inhibitory concentration of an antibiotic; API and RAPIDEC CARBA NP for identification of bacteria and manual antimicrobial susceptibility testing; BIOBALL for quantitative microbiological quality control; CHEMUNEX, a microbiology instrument; ENDONEXT for detection of endotoxins; TEMPO for fluorescence counting of bacteria; and Hybiome, a CLIA technology, as well as lab consultancy service and training modules. The company was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. operates as a subsidiary of Institut Mérieux SA.
bioMérieux S.A management
10- Mr. Pierre BouludChief Executive Officer · born 1971
- Mr. Guillaume BouhoursExecutive VP of Finance, Purchasing and Information Systems & CFO · born 1976
- Aymeric FichetHead of Investor Relations
- Ms. Audrey DauvetExecutive Vice President of Legal, Corporate Integrity & Public Affairs · born 1975
- Ms. Valerie LeyldeExecutive Vice President of Human Resources, Communications & CSR
- Mr. Pierre CharbonnierExecutive Vice President of Global Quality, Manufacturing & Supply Chain
- Mr. Yasha MitrottiExecutive Vice President of Industrial Applications
- Mr. Frederic BesemeHead of CSR · born 1956
- Ms. Jennifer ZinnExecutive Vice President of Clinical Operations
- Dr. Charles K. CooperExecutive VP of Medical Affairs & Chief Medical Officer